Market Research Logo

Leukemia Therapeutics Market by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs by (CLL, ALL, CML, AML)), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics), Gender, and Region - Global Forecast

Leukemia Therapeutics Market by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs by (CLL, ALL, CML, AML)), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics), Gender, and Region - Global Forecast to 2024

The study involved four major activities in estimating the current size of the leukemia therapeutics market. Exhaustive secondary research was done to collect information on the market and its subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.

Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.

Primary Research
Several stakeholders such as leukemia drug manufacturers, vendors, distributors and scientists, researchers, oncologist, and doctors from hospitals and clinics were consulted for this report. The demand side of this market is characterized by the significant use of immunotherapies and targeted drugs for leukemia treatment owing to the increasing incidence rate of leukemia across the globe. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

BREAKDOWN OF PRIMARY PARTICIPANTS:

Note 1: C-level primaries include chief executive officers (CEOs), chief operation officers (COOs), and chief financial officers (CFOs). D-level primaries include directors, managers, and heads of departments. Others include sales managers, marketing managers, and product managers.
Note 2: Company tiers are defined by their total revenues. As of 2017, Tier 1: >USD 1 billion; Tier 2: USD 50 million to USD 1 billion; and Tier 3: <50 million.

“To know about the assumptions considered for the study, download the pdf brochure.”

Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the leukemia therapeutics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
The key players in the industry and markets have been identified through extensive secondary research
The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation
After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the leukemia industry.

Report Objectives
To define, describe, and forecast the leukemia therapeutics market on the basis of type, application, and region
To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, and opportunities)
To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall leukemia therapeutics market
To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
To forecast the size of the market segments in four geographical regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
To track and analyze competitive developments such as product launches, partnerships, expansions, and acquisitions in the leukemia therapeutics market

Scope of the Report
Report Metric Details
Market Size Available for Years 2017–2024
Base Year Considered 2018
Forecast Period 2019–2024
Forecast Units Value (USD)
Segments Covered Leukemia therapeutics market by treatment type, type of leukemia, gender, molecule type, mode of administration, and region
Geographies Covered North America (US, Canada), Europe (Germany, France, UK, and the RoE), APAC (Japan, China, Australia, and the RoAPAC), and the RoW
Companies Covered Major 10 players covered—Novartis (Switzerland), AbbVie (US), Bristol-Myers Squibb (US), F. Hoffmann-La Roche (Switzerland), Sanofi (France), Pfizer (US), Amgen (US), Gilead Sciences (US), Takeda Pharmaceutical (Japan), and Celgene (US)

This research report categorizes the leukemia therapeutics market into the following segments and subsegments:
LEUKEMIA THERAPEUTICS MARKET, BY TYPE OF LEUKEMIA
Acute lymphocytic leukemia (ALL)
Chronic lymphocytic leukemia (CLL)
Acute myeloid leukemia (AML)
Chronic myeloid leukemia (CML)
LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE
Targeted drugs & immunotherapy
Chemotherapy
LEUKEMIA THERAPEUTICS MARKET, BY MOLECULE TYPE
Small Molecules
Biologics

LEUKEMIA THERAPEUTICS MARKET, BY MODE OF ADMINISTRATION
Injectable
Oral
LEUKEMIA THERAPEUTICS MARKET, BY GENDER
Male
Female
LEUKEMIA THERAPEUTICS MARKET, BY REGION

North America
US
Canada
Europe
Germany
UK
France
Rest of Europe
Asia Pacific
China
Japan
India
Rest of Asia Pacific
Rest of the World

Available Customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Product Analysis: Product matrix, which gives a detailed comparison of the product portfolios of each company
Geographic Analysis: Further breakdown of the European, Asia Pacific, and the Rest of the World segments into their respective countries for this market
Company Information: Detailed analysis and profiling of additional market players (up to 5)
Volume Data: Customization options for volume data (number of units sold) and customization options for volume data (number of tests)
Opportunities Assessment: A detailed report underlining the various growth opportunities presented in the market

Related Reports:
INTERVENTIONAL ONCOLOGY MARKET - GLOBAL FORECAST TO 2024
By Product (Radiofrequency, microwave, cryoablation, embolization, guidewires), Procedures (Thermal Ablation, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung, Kidney, Bone Metastasis)

STEM CELL ASSAY MARKET - GLOBAL FORECAST TO 2023
By Type (Viability, Purification, Identification), Cell Type (Mesenchymal, iPSCs, HSCs, hESCs), Product & Service (Instruments, Kits), Application (Regenerative Medicine, Clinical Research), End User


  • INTRODUCTION
    • OBJECTIVES OF THE STUDY
    • MARKET DEFINITION
      • MARKETS COVERED
      • YEARS CONSIDERED FOR THE STUDY
    • CURRENCY
    • LIMITATIONS
    • STAKEHOLDERS
  • RESEARCH METHODOLOGY
    • RESEARCH DATA
    • SECONDARY DATA
      • KEY DATA FROM SECONDARY SOURCES
    • PRIMARY DATA
      • KEY DATA FROM PRIMARY SOURCES
    • MARKET SIZE ESTIMATION
      • BOTTOM-UP APPROACH
      • TOP-DOWN APPROACH
    • MARKET BREAKDOWN AND DATA TRIANGULATION
    • ASSUMPTIONS FOR THE STUDY
  • EXECUTIVE SUMMARY
  • PREMIUM INSIGHTS
    • LEUKEMIA THERAPEUTICS: MARKET OVERVIEW
    • LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE & MODE OF ADMINISTRATION (2019)
    • GEOGRAPHICAL SNAPSHOT OF THE LEUKEMIA THERAPEUTICS MARKET
  • MARKET OVERVIEW
    • INTRODUCTION
    • MARKET DYNAMICS
      • DRIVERS
        • Table LEUKEMIA PATIENTS, BY REGION
        • Table ACUTE LYMPHOCYTIC LEUKEMIA PATIENTS IN US
      • RESTRAINTS
      • OPPORTUNITIES
  • LEUKEMIA THERAPEUTICS MARKET, BY TYPE OF LEUKEMIA
    • INTRODUCTION
      • Table LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)
    • CHRONIC MYELOID LEUKEMIA
      • CHRONIC MYELOID LEUKEMIA ACCOUNTS FOR THE LARGEST SHARE OF THE LEUKEMIA THERAPEUTICS MARKET PRIMARILY DUE TO THE HIGH INCIDENCE OF THIS DISEASE WORLDWIDE
        • Table CHRONIC MYELOID LEUKEMIA MARKET, BY REGION, 2017–2024 (USD MILLION)
    • CHRONIC LYMPHOCYTIC LEUKEMIA
      • THE INCIDENCE OF CHRONIC LYMPHOCYTIC LEUKEMIA INCREASES WITH AGE AND IS MORE COMMON IN MEN THAN WOMEN
        • Table CHRONIC LYMPHOCYTIC LEUKEMIA MARKET, BY REGION, 2017–2024 (USD MILLION)
    • ACUTE LYMPHOCYTIC LEUKEMIA
      • ACUTE LYMPHOCYTIC LEUKEMIA MOSTLY AFFECTS CHILDREN BETWEEN 3 AND 7 YEARS OF AGE
        • Table ACUTE LYMPHOCYTIC LEUKEMIA MARKET, BY REGION, 2017–2024 (USD MILLION )
    • ACUTE MYELOID LEUKEMIA
      • ACUTE MYELOID LEUKEMIA IS THE MOST COMMON ACUTE LEUKEMIA AFFECTING ADULTS
        • Table ACUTE MYELOID LEUKEMIA MARKET, BY REGION, 2017–2024 (USD MILLION)
  • LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE
    • INTRODUCTION
      • Table LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)
    • TARGETED DRUGS & IMMUNOTHERAPY
      • TARGETED DRUGS & IMMUNOTHERAPY SEGMENT ACCOUNTS FOR THE LARGER MARKET SHARE DUE TO THE HIGHER EFFICACY & SUCCESS RATE ASSOCIATED WITH THEM AS COMPARED TO CHEMOTHERAPY
        • Table TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)
        • Table TARGETED DRUGS AND IMMUNOTHERAPY MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)
        • Table TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)
        • Table TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)
        • Table TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR CHRONIC MYELOID LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)
        • Table TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR ACUTE MYELOID LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)
    • CHEMOTHERAPY
      • CHEMOTHERAPY IS EFFECTIVE AND ESSENTIAL FOR CANCERS SUCH AS LEUKEMIA THAT HAVE SPREAD THROUGHOUT THE BODY
        • Table FEW EXAMPLES OF CHEMOTHERAPY DRUGS
        • Table CHEMOTHERAPY MARKET FOR LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)
        • Table CHEMOTHERAPY MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)
        • Table CHEMOTHERAPY MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)
        • Table CHEMOTHERAPY MARKET FOR CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)
        • Table CHEMOTHERAPY MARKET FOR CHRONIC MYELOID LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)
        • Table CHEMOTHERAPY MARKET FOR ACUTE MYELOID LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)
  • LEUKEMIA THERAPEUTICS MARKET, BY MOLECULE TYPE
    • INTRODUCTION
      • Table LEUKEMIA THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017–2024 (USD MILLION)
    • SMALL MOLECULES
      • THE SMALL STRUCTURE AND CHEMICAL COMPOSITION OF SMALL MOLECULES HELP THEM TO EASILY PENETRATE CELL MEMBRANES
        • Table FEW IMPORTANT SMALL MOLECULES USED TO TREAT DIFFERENT LEUKEMIA TYPE
        • Table LEUKEMIA THERAPEUTICS MARKET FOR SMALL MOLECULES, BY REGION, 2017–2024 (USD MILLION)
    • BIOLOGICS
      • THIS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
        • Table FEW IMPORTANT BIOLOGICS FOR THE TREATMENT OF DIFFERENT LEUKEMIA TYPE
        • Table LEUKEMIA THERAPEUTICS MARKET FOR BIOLOGICS, BY REGION, 2017–2024 (USD MILLION)
  • LEUKEMIA THERAPEUTICS MARKET, BY MODE OF ADMINISTRATION
    • INTRODUCTION
      • Table LEUKEMIA THERAPEUTICS MARKET, BY MODE OF ADMINISTRATION, 2017–2024 (USD MILLION)
    • ORAL MODE
      • DRUGS ADMINISTERED ORALLY HAVE LESSER COMPLICATIONS
        • Table LEUKEMIA THERAPEUTICS MARKET FOR ORAL MODE OF ADMINISTRATION, BY REGION, 2017–2024 (USD MILLION)
    • INJECTABLE MODE
      • INJECTABLE MODE OF ADMINISTRATION IS LESS PREFERRED THAN THE ORAL MODE OF ADMINISTRATION
        • Table LEUKEMIA THERAPEUTICS MARKET FOR INJECTABLE MODE OF ADMINISTRATION, BY REGION, 2017–2024 (USD MILLION)
  • LEUKEMIA THERAPEUTICS MARKET, BY GENDER
    • INTRODUCTION
      • Table LEUKEMIA AT A GLANCE (US)
      • Table GLOBAL LEUKEMIA CASES (2018), BY COUNTRY AND GENDER & FORECAST (2020)
      • Table LEUKEMIA INCIDENCE AND DEATHS, BY GENDER (2018)
      • Table LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)
    • MALES
      • MEN ARE AT HIGHER RISK OF DEVELOPING LEUKEMIA THAN WOMEN
        • Table LEUKEMIA THERAPEUTICS MARKET FOR MALES, BY REGION, 2017–2024 (USD MILLION)
    • FEMALES
      • ACUTE LYMPHOCYTIC LEUKEMIA REMAINS COMMON AMONG WOMEN
        • Table LEUKEMIA THERAPEUTICS MARKET FOR FEMALES, BY REGION, 2017–2024 (USD MILLION)
  • LEUKEMIA THERAPEUTICS MARKET, BY REGION
    • INTRODUCTION
      • Table LEUKEMIA THERAPEUTICS MARKET, BY REGION, 2017–2024 (USD MILLION)
    • NORTH AMERICA
      • Table NORTH AMERICA: LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
      • Table NORTH AMERICA: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)
      • Table NORTH AMERICA: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)
      • Table NORTH AMERICA: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)
      • US
        • Table US: LEUKEMIA AT A GLANCE
        • Table US: LEUKEMIA, BY TYPE (2017 VS. 2018)
        • Table US: LEUKEMIA NEW CASES & DEATHS, BY STATE (2019)
        • Table US: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)
        • Table US: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)
        • Table US: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)
      • CANADA
        • Table CANADA: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)
        • Table CANADA: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)
        • Table CANADA: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)
    • EUROPE
      • Table RESEARCH FUNDING: EUROPEAN OVERVIEW
      • Table EUROPE: LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
      • Table EUROPE: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)
      • Table EUROPE: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)
      • Table EUROPE: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)
      • GERMANY
        • Table GERMANY: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)
        • Table GERMANY: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)
        • Table GERMANY: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)
      • UK
        • Table UK: NUMBER OF NEW CASES, CRUDE, AND AGE-STANDARDIZED (AS) INCIDENCE RATE PER 100,000 POPULATION (ACUTE LYMPHOCYTIC LEUKEMIA)
        • Table UK: NUMBER OF NEW CASES, CRUDE, AND AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000 POPULATION (CHRONIC LYMPHOCYTIC LEUKEMIA)
        • Table UK: NUMBER OF NEW CASES, CRUDE, AND AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000 POPULATION (ACUTE MYELOID LEUKEMIA)
        • Table UK: NUMBER OF NEW CASES, CRUDE, AND AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000 POPULATION (CHRONIC MYELOID LEUKEMIA)
        • Table UK: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)
        • Table UK: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)
        • Table UK: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)
      • FRANCE
        • Table FRANCE: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)
        • Table FRANCE: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)
        • Table FRANCE: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)
      • REST OF EUROPE
        • Table ROE: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)
        • Table ROE: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)
        • Table ROE: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)
    • ASIA PACIFIC
      • Table APAC: LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
      • Table APAC: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)
      • Table APAC: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)
      • Table APAC: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)
      • JAPAN
        • Table JAPAN: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)
        • Table JAPAN: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)
        • Table JAPAN: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)
      • CHINA
        • Table CHINA: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)
        • Table CHINA: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)
        • Table CHINA: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)
      • INDIA
        • Table INDIA: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)
        • Table INDIA: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)
        • Table INDIA: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)
      • ROAPAC
        • Table ROAPAC: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)
        • Table ROAPAC: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)
        • Table ROAPAC: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)
    • REST OF THE WORLD
      • Table ROW: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)
      • Table ROW: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)
      • Table ROW: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)
  • COMPETITIVE LANDSCAPE
    • OVERVIEW
    • MARKET RANKING ANALYSIS, 2018
      • Table LEUKEMIA THERAPEUTICS MARKET RANKING BY KEY PLAYER, 2018
    • KEY STRATEGIES
      • REGULATORY APPROVALS/LAUNCHES
      • ACQUISITIONS
      • AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
    • COMPETITIVE LEADERSHIP MAPPING (2018)
      • VENDOR INCLUSION CRITERIA
      • VISIONARY LEADERS
      • INNOVATORS
      • DYNAMIC DIFFERENTIATORS
      • EMERGING COMPANIES
    • COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2018)
      • PROGRESSIVE COMPANIES
      • STARTING BLOCKS
      • RESPONSIVE COMPANIES
      • DYNAMIC COMPANIES
  • COMPANY PROFILES
    • NOVARTIS AG
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • ABBVIE
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • BRISTOL-MYERS SQUIBB
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
    • F. HOFFMANN-LA ROCHE
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • SANOFI
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
    • PFIZER
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM OVERVIEW
    • AMGEN
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
    • GILEAD SCIENCES
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • TAKEDA
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
    • CELGENE
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • REGULATORY APPROVALS
      • MNM VIEW
  • APPENDIX
    • INSIGHTS FROM INDUSTRY EXPERTS
    • DISCUSSION GUIDE
    • KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
    • AVAILABLE CUSTOMIZATIONS
    • RELATED REPORTS
    • AUTHOR DETAILS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report